Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
Status:
Not yet recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, single arm study looking at the rate of major pathological response in
Stage II and III colon cancer after 3 cycles of neoadjuvant Dostarlimab.